These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 12616342)

  • 1. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
    Efferth T; Sauerbrey A; Halatsch ME; Ross DD; Gebhart E
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):56-67. PubMed ID: 12616342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modes of action of artesunate in tumor cell lines.
    Efferth T; Sauerbrey A; Olbrich A; Gebhart E; Rauch P; Weber HO; Hengstler JG; Halatsch ME; Volm M; Tew KD; Ross DD; Funk JO
    Mol Pharmacol; 2003 Aug; 64(2):382-94. PubMed ID: 12869643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro.
    Zhou JY; Chen DL; Shen ZS; Koeffler HP
    Cancer Res; 1990 Apr; 50(7):2031-5. PubMed ID: 2317793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.
    Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Gupta RR; Molnár J
    Anticancer Res; 1998; 18(1A):337-48. PubMed ID: 9568100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An informatics approach identifying markers of chemosensitivity in human cancer cell lines.
    Amundson SA; Myers TG; Scudiero D; Kitada S; Reed JC; Fornace AJ
    Cancer Res; 2000 Nov; 60(21):6101-10. PubMed ID: 11085534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homoharringtonine production by endophytic fungus isolated from Cephalotaxus hainanensis Li.
    Hu X; Li W; Yuan M; Li C; Liu S; Jiang C; Wu Y; Cai K; Liu Y
    World J Microbiol Biotechnol; 2016 Jul; 32(7):110. PubMed ID: 27263005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of harringtonine-resistant human leukemia HL60 cell.
    He QY; Zhou WD; Ji L; Zhang HQ; He NG; Xue SB
    Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):463-7. PubMed ID: 9863176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine.
    Russo D; Michelutti A; Melli C; Damiani D; Michieli MG; Candoni A; Zhou DC; Marie JP; Zittoun R; Baccarani M
    Leukemia; 1995 Mar; 9(3):513-6. PubMed ID: 7885049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
    Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
    Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of ascaridol from the anthelmintic herb Chenopodium anthelminticum L. against sensitive and multidrug-resistant tumor cells.
    Efferth T; Olbrich A; Sauerbrey A; Ross DD; Gebhart E; Neugebauer M
    Anticancer Res; 2002; 22(6C):4221-4. PubMed ID: 12553060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative activity of colchicine analogues on MDR-positive and MDR-negative human cancer cell lines.
    De Vincenzo R; Scambia G; Ferlini C; Distefano M; Filippini P; Riva A; Bombardelli E; Pocar D; Gelmi ML; Benedetti Panici P; Mancuso S
    Anticancer Drug Des; 1998 Jan; 13(1):19-33. PubMed ID: 9474240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia.
    Efferth T; Sauerbrey A; Steinbach D; Gebhart E; Drexler HG; Miyachi H; Chitambar CR; Becker CM; Zintl F; Humeny A
    Int J Oncol; 2003 Aug; 23(2):509-17. PubMed ID: 12851703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microarray-based prediction of cytotoxicity of tumor cells to cantharidin.
    Efferth T
    Oncol Rep; 2005 Mar; 13(3):459-63. PubMed ID: 15706417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin.
    Weinstein-Oppenheimer CR; Henríquez-Roldán CF; Davis JM; Navolanic PM; Saleh OA; Steelman LS; Franklin RA; Robinson PJ; McMahon M; McCubrey JA
    Clin Cancer Res; 2001 Sep; 7(9):2898-907. PubMed ID: 11555608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C; Wellham LL
    Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for and identification of novel agents directed at renal cell carcinoma.
    Mertins SD; Myers TG; Hollingshead M; Dykes D; Bodde E; Tsai P; Jefferis CA; Gupta R; Linehan WM; Alley M; Bates SE
    Clin Cancer Res; 2001 Mar; 7(3):620-33. PubMed ID: 11297258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
    Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NCI's anticancer drug screening program may not be selecting for clinically active compounds.
    Brown JM
    Oncol Res; 1997; 9(5):213-5. PubMed ID: 9306428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.